Watch RYTM. Know when insiders buy.
One email the day a filing lands. Free.
Work order
29
FLAG · insiders 25, shorts 32
Insiders, 90 days
−$6.6M
net selling · 0 buys, 3 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
1 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $7.1BP/E —DIV YIELD —FCF YIELD —REV TTM $239.9M +53.5%NET INCOME −$205.3MNET DEBT $7.3M52W 75.82 – 117.62SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $71.3M | +46.9% | 87.5% | −$48.6M | −$49.3M | — | -0.73 | −$9.2M | — | — | Aug 4 |
| Q1 2026 · Mar 31 | $60.1M | +83.8% | 88.1% | −$52.4M | −$55.6M | — | -0.83 | −$44.2M | — | — | Aug 4 |
| Q4 2025 · Dec 31derived | $57.3M | +36.9% | 91.6% | −$47.1M | −$47.5M | — | -0.73 | −$25.4M | — | — | Feb 26 |
| Q3 2025 · Sep 30 | $51.3M | +54.3% | 89.3% | −$52.7M | −$52.9M | — | -0.82 | −$26.6M | — | — | Nov 4 |
| Q2 2025 · Jun 30 | $48.5M | +66.8% | 88.6% | −$45.3M | −$46.6M | — | -0.75 | −$23.3M | — | — | Aug 4 |
| Q1 2025 · Mar 31 | $32.7M | +25.9% | 88.8% | −$47M | −$49.5M | — | -0.81 | −$40.4M | — | — | Aug 4 |
| Q4 2024 · Dec 31derived | $41.8M | +72.6% | 90.9% | −$41.3M | −$43.3M | — | -0.72 | −$18.8M | — | — | Feb 26 |
| Q3 2024 · Sep 30 | $33.3M | +47.8% | 88.5% | −$43.9M | −$43.6M | — | -0.73 | −$25.2M | — | — | Nov 4 |
| Q2 2024 · Jun 30 | $29.1M | — | 89.9% | −$40.5M | −$32.3M | — | -0.55 | −$29.1M | — | — | Nov 4 |
| Q1 2024 · Mar 31 | $26M | — | 89.2% | −$139.9M | −$141.4M | — | -2.35 | −$40.7M | — | — | Nov 4 |
| Q4 2023 · Dec 31derived | $24.2M | — | 86.7% | −$41.3M | −$41.6M | — | -0.70 | −$29.4M | −$1K | −$29.4M | Feb 26 |
| Q3 2023 · Sep 30 | $22.5M | — | 89.3% | −$44M | −$44.2M | — | -0.76 | −$29.3M | $1K | −$29.3M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $189.8M | 89.7% | −$192M | −$196.5M | -103.6% | -3.11 | −$115.7M | $953K | −$116.6M | — | — |
| FY2024 · to Dec 31 | $130.1M | 89.7% | −$265.5M | −$260.6M | -200.3% | -4.34 | −$113.9M | $0 | −$113.9M | — | — |
| FY2023 · to Dec 31 | $77.4M | 88.0% | −$184.4M | −$184.7M | -238.5% | -3.20 | −$136.2M | $47K | −$136.2M | — | — |
| FY2022 · to Dec 31 | $23.6M | 91.0% | −$179.2M | −$181.1M | -766.2% | -3.47 | −$173.4M | $281K | −$173.7M | — | — |
| FY2021 · to Dec 31 | $3.2M | 81.0% | −$170.1M | −$69.6M | -2207.1% | -1.40 | −$146M | $434K | −$146.4M | — | — |
| FY2020 · to Dec 31 | — | — | −$136.6M | −$134M | — | -3.04 | −$122M | $214K | −$122.2M | — | — |
Every number comes from RHYTHM PHARMACEUTICALS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.